The FDA has kicked off a priority review of a new combination regimen for previously untreated, locally advanced or metastatic urothelial carcinoma (UC), the most common f
In the last decade, immunotherapy with PD-1/PD-L1 inhibitors has transformed the treatment of relapsed urothelial carcinoma (UC), the most common form of bladder cancer.
A combination of Astellas and Seagen’s Padcev with MSD’s Keytruda has significantly improved survival compared to chemotherapy in previously untreated patients with advanc
NICE has recommended routine use of Bristol-Myers Squibb's Opdivo for the adjuvant treatment of some patients with urothelial carcinoma (UC), the most common form of bladder cancer.
Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<
Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance treatment with Merck Serono and Pfizer's Bavencio, ahead of their counterparts in England
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.